Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Cancer Cell(2021)10.1016/j.ccell.2021.06.001Source: DataRank Database

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 0. It has been cited 103 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access103 citations

Download PDF

Cite:

Linked data & code

gen pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 5.03)OA: bronzeTopics (70)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Benjamin P. Brown ORCID,Jens Meiler ORCID,Arnaldo Marín ORCID,Harikrishna Sekar Jayanthan,Dan Ye ORCID

Live enrichment

PubMed:34171264 PMC:PMC8355076 OpenAlex:https://openalex.org/W3175821404

Cancer Prevention and Research Institute of Texas

Grant: RR170061

National Cancer Institute

Grant: R01CA224899

UT Southwestern

Grant: P30 CA142543

Susan G Komen for the Cure

Grant: SAB1800010

Vanderbilt-Ingram Cancer Center

Grant: P30 CA68485

NCI NIH HHS

Grant: P30 CA068485

NIH HHS

Grant: S10 OD023680

NCI NIH HHS

Grant: P50 CA098131

NIDDK NIH HHS

Grant: F30 DK118774

NIGMS NIH HHS

Grant: T32 GM007347

NIAID NIH HHS

Grant: R56 AI110750

NIGMS NIH HHS

Grant: T32 GM152284

Breast Cancer Research Foundation

Daiichi-Sankyo

AstraZeneca

Israel National Road Safety Authority

Merck

NIH

FWCI

5.03

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S1535610821002841/pdf

publisherhttp://www.cell.com/article/S1535610821002841/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610821002841?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610821002841?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2021.06.001

Fields of Study

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchAminopyridinesAnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmFemaleGain of Function MutationHumansMice, NudeMolecular Docking SimulationMolecular Dynamics SimulationMorpholinesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein MultimerizationQuinolinesErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3TrastuzumabXenograft Model Antitumor AssaysMice

MeSH Terms

TrastuzumabGain of Function MutationPhosphoinositide-3 Kinase InhibitorsAminopyridinesAnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansMice, NudeMorpholinesQuinolinesReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesDrug Resistance, NeoplasmPhosphatidylinositol 3-KinasesReceptor, ErbB-3Xenograft Model Antitumor AssaysCell Line, TumorMiceProtein MultimerizationMolecular Dynamics SimulationMolecular Docking SimulationReceptor, erbB-3

Keywords

Gain of functionCarcinogenesisFunction (biology)Loss functionCancer researchBiologyMutationCancerCell biologyGeneticsGenePhenotypeBreast cancerMolecular dynamicsPI3KHer2Her3NeratinibRosettaPrecision OncologyPersonalized Structural Biology

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (2)

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

N/A

1.4DataRank · unranked

Annals of Oncology(2023)

co-cited

10.1016/j.annonc.2023.08.003

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

N/A

1.2DataRank · unranked

Nature Medicine(2017)

co-cited

10.1038/nm.4333

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

FAIR Checklist

Authors (18)

Funding (18 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)

Related Papers (2)